59 results
8-K
EX-99.5
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
of upfront costs or training required for physicians to administer Kineta’s product candidates;
the availability of coverage, adequate reimbursement from … , recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate
8-K
EX-10.6
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
staff training initiatives; (26) objective goals relating to projects, including project completion, timing and/or achievement of milestones, project
424B3
9091my1
10 Nov 22
Prospectus supplement
4:21pm
8-K
EX-10.1
al2490ac
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
zu8p2gmm9x2gbc9
16 Aug 21
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
7:21am